Anavex Life Sciences Corp.
51 West 52nd Street
7th floor
New York
New York
10019
United States
Tel: 1-844-689-3939
Website: http://www.anavex.com/
Email: info@anavex.com
302 articles with Anavex Life Sciences Corp.
-
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
5/10/2022
Anavex Life Sciences Corp. reported financial results for its fiscal quarter ended March 31, 2022.
-
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022 Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET
5/3/2022
Anavex Life Sciences Corp. today announced that it will issue financial results for its fiscal quarter ended March 31, 2022 on Tuesday May 10, 2022.
-
Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
4/27/2022
Anavex Life Sciences Corp. announced presentations of Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire and Burden of Illness study in Rett syndrome by the respective working groups, at the IRSF Rett Syndrome Scientific Meeting, taking place in Nashville, TN, April 26–27, 2022.
-
Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
4/26/2022
Anavex Life Sciences Corp. announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022, at 11:00 AM ET.
-
Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
4/7/2022
Anavex Life Sciences Corp. announced that Anavex Management Team will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 3:45 PM ET.
-
Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
3/28/2022
Anavex Life Sciences Corp. announced that Anavex Management team will participate in the Rare Neurodevelopmental Disorders Panel at the Cantor Virtual Rare Disease Summit on Wednesday, March 30, 2022 at 11:00 AM ET.
-
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
3/15/2022
Anavex Life Sciences Corp. today announced the presentation of Phase 2 clinical biomarker data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at AD/PD™ 2022 International Conference on Alzheimer’s & Parkinson’s Diseases and related neurological disorders, taking place in Barcelona, Spain, and virtually on March 15–20, 2022.
-
Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
3/9/2022
Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the Annual Needham Virtual Neuroscience Forum in a fireside chat on Wednesday, March 16th 2022 at 8:00 AM ET.
-
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
3/4/2022
Anavex Life Sciences Corp. today announced that it has changed its auditors from BDO USA LLP (“BDO“) to Grant Thornton LLP.
-
Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Anavex Life Sciences Corp. announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference and present on Wednesday, February 16 at 3 pm ET.
-
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results
2/9/2022
Anavex Life Sciences Corp. reported financial results for its fiscal quarter ended December 31, 2021.
-
It was a relatively quiet week for clinical trial announcements. Here’s a look.
-
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
2/4/2022
Anavex Life Sciences Corp. today provides supplemental information on the ANAVEX®2-73 treatment.
-
Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022
2/3/2022
Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended December 31, 2021 on Wednesday, February 9, 2022.
-
The press release has been shrouded with controversy, and the company’s stock fell 16% despite the seemingly optimistic results.
-
Anavex Life Sciences announced positive topline results from its Phase III AVATAR trial of Anavex 2-73 (blarcamesione) in adult female patients with Rett syndrome.
-
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
2/1/2022
Anavex Life Sciences today reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX®2-73
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
1/10/2022
Anavex Life Sciences Corp. announced positive top-line results from its Phase 1 clinical trial of ANAVEX®3-71, an oral small molecule agonist of both SIGMAR1 and CHRM1 in development for the treatment of neurodegenerative diseases including Frontotemporal Dementia, for which ANAVEX®3-71 has been granted Orphan Drug Designation by the FDA.
-
Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
1/6/2022
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced that Walter E Kaufmann, M.D. has been promoted to Chief Scientific Officer and Edward R Hammond, M.D., M.P.H., PhD, has been appointed Chief Medical Officer.